Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
13/10/2026 13:05
BRIEF-Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis Oct 13 (Reuters) - NovaBridge Biosciences NBP.O:
VISARA EXPANDS OPHTHALMOLOGY PIPELINE WITH EXCLUSIVE LICENSE FOR INVESTIGATIONAL NERVE GROWTH FACTOR THERAPY FOR NEUROTROPHIC KERATITIS
VISARA: SECURES EXCLUSIVE WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE HT006.2.2 EXCLUDING GREATER CHINA
VISARA: ENTERS EXCLUSIVE LICENSE AGREEMENT WITH WUHAN HITECK FOR VIS-102
VISARA: HITECK TO RECEIVE UP-FRONT PAYMENT, MILESTONE PAYMENTS, AND TIERED ROYALTIES ON NET SALES
Source text: ID:nGNX9jybsS
Further company coverage: NBP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NovaBridge Biosciences
See all newsBrief: Visara Secures Exclusive Option For Potential Acquisition Of Yol104-2 For Ocular Surface Squamous Neoplasia
Brief: Visara Expands Ophthalmology Pipeline With Exclusive License For Investigational Nerve Growth Factor Therapy For Neurotrophic Keratitis
Brief: Wuhan Hiteck Biological Pharma Grants Visara Exclusive Rights To HT006.2.2 Outside Greater China
Brief: Novabridge Biosciences Announces Expanded Givastomig Safety And Efficacy Data
NovaBridge Biosciences expected to post a loss of 13 cents a share - Earnings Preview